The concept behind the SentoClone® technology was developed at the Karolinska Institutet in Stockholm in 1999 by immunologist Ola Winqvist and the surgeon Magnus Thörn . The first patent application was filed in 2002 and a pilot study in patients was initiated later the same year at the Karolinska Institutet.
The company SentoClone was formed in 2004 and received private and public funding of around 15 MEUR over the following years. In 2007 the company was awarded its first European patent. This has been followed by a number of patents granted all over the world, including, as of March 2013, another two in Europe, six in the U.S. and one in Japan.
In total 103 patients have been treated by the adaptive immunotherapy developed by SentoClone in Sweden between 2003 and 2010. Since 2010, the Company is owned by the Chinese company Jiangsu Sinorda Biomedicine Co., Ltd which develops the method in China. The Swedish subsidiary SentoClone International will develop the technology to a global pharmaceutical product for all markets outside China. The clinical development is presently performed in China at the facilities of the parent company.
SentoClone® is classified as a cell based medicinal product under the European regulation on advanced therapy medicinal products (ATMP). The registration pathway is the centralised procedure, co-ordinated by the EMEA for all EU (and EEA) countries.